blocking antibodies, have had limited success, necessitating the development of novel therapeutic strategies. Chimeric Antigen Receptor T-cell therapy (CAR-T) targets autoreactive B cells and reduces disease activity
Chimeric Antigen Receptor (CAR) T-cell therapy represents a paradigm shift in cancer immunotherapy, offering a highly targeted approach for treating hematological malignancies and solid tumors. This therapy involves…
mechanisms. The Epithelial Cell Adhesion Molecule (EpCAM) has emerged as a potential target for Chimeric Antigen Receptor (CAR) T cell therapy. However, the efficacy of this promising treatment is hampered
high incidence of different resistance to current therapeutic treatments. One of the immunotherapies, the chimeric antigen receptor T (CAR-T) cells therapy, has proven to have a potent ability
rates and long-lived malady management due to the event of COVID-19-targeted Chimerical matter receptor (CAR) T-cells. Automobile T-cells will cause protein unleash syndrome, neurotoxicities, cytopenia
Challenges present with chimeric antigen receptors (CARs) adoptive cell therapy against solid tumors have been lacking a ubiquitous tumor-associated antigen across different tumor types, tumor antigen expression…
recombinant strain constitute by Penton and Fiber proteins belonging to type 89 and a chimeric Hexon protein of type 1 and 89. By using viral metagenomics techniques, we screened
Teff and Treg balance with demonstrated clinical efficacy in cancer immunotherapy. We generated a chimeric PD-L1 molecule that can be transiently displayed on the surface of pancreatic islets
workshop will start with a review of the chimeric antigen receptor (CAR) and CAR engineered T cells, and segue into an introduction of a novel universal CAR, the Adapter
research endeavors searching for a novel and efficacious treatment for oncologic disease, including glioblastoma. Chimeric Antigen Receptor (CAR)-T-cells consist of a single chain variable fragment of a monoclonal
Recent approval of chimeric antigen receptor T-cell immunotherapy (CAR-T) for the clinical use represents a significant progress in the human defense war against cancer, and validates a novel
bone marrow transplant. More recently, a form of antibody-mediated immunotherapy using genetically engineered chimeric antigen receptor (CAR) T-cells has been used in several clinical trials with encouraging results
immunogenic sites of surface pneumococcal proteins could be an advantageous vaccine alternative. Methods: A chimeric recombinant protein named PSPF was constructed from conservative and immunogenic fragments of S…
Chimeric antigen receptor T (CART) cell therapy represents a novel, potent and potentially curative therapy in hematological malignancies. CD19 directed CARTs have resulted in impressive complete response rates
based on simple covalent coupling between known anti-cancer drugs, which results in novel 'chimeric' small molecules. One of the novel compounds presented here, CM358, is a result of amide
Infliximab is a chimeric, monclonal antibody against tumour necrosis factor α. Extending previous findings in other chronic inflammatory diseases, recent double-blind, placebocontrolled, randomized trials have provided…
have evaluated for the first time the safety and efficacy of EGFR-targeted chimeric antigen receptor-modified T (CAR-T) cells in patients with epidermal growth factor receptor (EGFR) positive
virus (HCV) formulated with lipid nanoparticles was able to suppress viral replication in chimeric mice infected with HCV GT1a by up to 2.5 log10. Viral load remained about 1 log10
testable approach in this front. Following the clinical success of adoptive transfer of chimeric antigen-receptor (CAR)-modified T cells as a treatment for hematological cancers, we designed three
treat a variety of inherited and acquired diseases. BMT leading to mixed allogeneic hematopoietic chimerism (MAC) can be used as an immunomodulatory approach to induce tolerance to auto-, allo
widely accepted technique used for personal identification, by forensic scientist all over the world. Chimerism generates a potential challenge for correct identification of an individual because recipient acquires…
tumor suppressor gene initially identified based on its inactivation in Wilms tumor. The chimeric proteins resulting from these chromosomal translocations usually possess gain-of-function transcriptional activities and…